STOCK TITAN
  1. Home
  2. News
  3. JAGX

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

News
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Rhea-AI Summary
Jaguar Health appoints biopharmaceutical industry veteran to execute company's in-licensing growth strategy in cancer and GI supportive care. Catherine Miller Collis joins the company with a wealth of experience in the industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Rhea-AI Summary
Jaguar Health licenses FDA-approved oral mucositis product, Gelclair, for the U.S. market, aiming to address the significant adverse event in oncology. The company plans to launch in Q3 2024, expanding its focus to cancer supportive care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.83%
Tags
none
-
News
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Rhea-AI Summary
Jaguar Health, Inc. announces the voting results of the Special Meeting of Stockholders, approval of four proposals, and the extension of the grace period by Nasdaq. The company will not implement a reverse split at this time. Top line results for the Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea are expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.89%
Tags
none
News
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Rhea-AI Summary
Jaguar Health, Inc. announces an extension of the grace period by Nasdaq for regaining compliance with the $1.00 bid price requirement. The company's phase 3 OnTarget trial of crofelemer for preventing cancer therapy-related diarrhea is ongoing, with top-line results expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
-
News
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Rhea-AI Summary
Jaguar Health, Inc. appoints Dr. Massimo Radaelli as President of Jaguar International, focusing on expanding commercial footprint globally. Dr. Radaelli's expertise in the pharmaceutical industry and rare disease therapies brings valuable leadership to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
management
-
News
Jaguar Health Reports 2023 Financial Results
Rhea-AI Summary
Jaguar Health, Inc. reported a decrease in net revenue for the year ended December 31, 2023, compared to 2022. The company's phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea is ongoing, with top-line results expected soon. Financially, there was a decrease in net revenue, loss from operations, and net loss attributable to common stockholders. However, interest expenses decreased, and there was a gain on extinguishment of debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.35%
Tags
earnings
News
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) will hold an investor webcast on April 1, 2024, to discuss fourth-quarter 2024 financials and corporate updates. The company plans to file its Earnings Report on April 1, 2024, on Form 10-K for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
earnings
-
News
GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Rhea-AI Summary
Jaguar Health, Inc. announced a binding term sheet with Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret, A.S. for the exclusive license and commercialization of crofelemer. The agreement includes a $2 million investment by GEN in Jaguar stock, double-digit royalties to Jaguar on all crofelemer products sold, and manufacturing and marketing rights for various indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.97%
Tags
none
-
News
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) provides an update on its Nasdaq listing status, facing potential delisting due to low stock prices. The company has requested a hearing, and the stock will continue trading pending the appeal decision. Jaguar is working on data analysis for its Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
News
Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Rhea-AI Summary
Jaguar Health, Inc. (JAGX) announces agreement with FDA for a clinical field study of Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs. The drug received conditional approval in December 2021 and is the first of its kind. The study aims for full approval by collecting evidence of effectiveness. Canalevia-CA1 helps dogs undergoing chemotherapy by improving comfort and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
clinical trial
Stock JAGX logo
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

#4762 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

JAGX Stock Data

24.94M
274.29M
1.78%
0.45%
8.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/